Source: Financial Modeling Prep · peers by sector/industry
Insider activity (SEC Form 4)
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Valuation
Trading at 252.8× sales vs its 189.1× historical median P/S.
Fair value ≈ $3.26 · price $4.36 today
Overvalued · 34% above
Loading valuation…
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.
$BTAI $ADVM $TPST $CODX
Phase 3 SERENITY At Home data is an absolute monster. They tracked over 2,400 agitation episodes. For severe agitation, complete resolution hit 61% for BXCL501 versus just 18% for placebo with a p value of <0.0001. Overall resolution was 50% versus 33% (p < 0.0001). The efficacy is undeniable. This is an already approved drug expanding into a massive 86M episode market. PDUFA is locked for Nov 14. The science is completely de risked. Once management clears the financial overhang, there is zero resistance left. Loading up while the crowd is distracted.
$BTAI$CODX $TPST $ADVM
Phase 3 SERENITY At Home data is an absolute monster. They tracked over 2,400 agitation episodes. For severe agitation, complete resolution hit 61% for BXCL501 versus just 18% for placebo with a p value of <0.0001. Overall resolution was 50% versus 33% (p < 0.0001). The efficacy is undeniable. This is an already approved drug expanding into a massive 86M episode market. PDUFA is locked for Nov 14. The science is completely de risked. Once management clears the financial overhang, there is zero resistance left. Loading up while the crowd is distracted.
$CABA Book it. "Yes, it is highly likely—almost standard practice—for a biotechnology company to schedule a conference call, webcast, or investor event to release positive clinical trial data.
In RESET-MG, data will be presented in an oral presentation at 1:24 p.m. CDT on Monday, April 20, 2026"
$CTNM $SANA $ADVM
$ADVM Outstanding article that hits the mark on ADVM's current state. So if you want to refresh your ADVM insights or learn about ADVM from scratch, this is a must read. https://everyticker.com/quote/ADVM/analysis/adverum-biotechnologies-gene-therapy-s-shot-at-wet-amd-fueled-by-data-facing-funding-headwinds-advm
$ADVM The investment case increasingly rests on operational credibility rather than long‑range promises. Competitive differentiation needs clearer proof points. A series of confirmed wins might reduce the required risk premium. Execution precision will determine whether this evolves or stalls.
$ADVM ADVM
The halt was related to the pending acquisition of Adverum Biotechnologies (ADVM) by Eli Lilly and Company.
Here are the details of the offer by Eli Lilly and Company to acquire Adverum Biotechnologies, Inc. (ADVM):
💰 Acquisition Terms
The total potential value of the transaction is up to $12.47 per share, structured as follows:
Component Value Per Share Type Details
Upfront Cash Payment $3.56 Cash Paid upon the closing of the tender offer. This gives stockholders immediate liquidity.
Contingent Value Right (CVR) Up to $8.91
$ADVM Equity Corporate Actions Alert #2025 - 666
Information Regarding the Tender Offer of Adverum Biotechnologies, Inc. (ADVM)
https://www.nasdaqtrader.com/TraderNews.aspx?id=ECA2025-666
The tender offer by Eli Lilly and Company. ($LLY) to acquire all of the outstanding common stock of Adverum Biotechnologies, Inc. (ADVM) is scheduled to expire one minute after 11:59 p.m. ET, on December 8, 2025, unless extended or terminated. The subsequent merger is tentatively scheduled to close prior to the market open on December 9, 2025. In anticipation of the closing, the stock will be halted immediately following the after-hours session at or around 7:50 p.m. on December 8, 2025. If the merger closes as planned, the stock will remain halted on the day of closing (December 9th) and will be suspended effective December 10, 2025.
ADVM shareholders will receive $3.56 and a CVR for each share held at closing.
